Steven George Hughes is the Chief Medical Officer at Atrium Therapeutics, Inc. (RNA). SEC records also connect Hughes to Avidity Biosciences, Inc. (RNAM). Hughes has reported 9 insider filings with the SEC since 2025. The most recent filing was in April 2026.
Every role Steven George Hughes has reported on a Form 4, reconstructed from the filings themselves. Reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
Atrium Therapeutics, Inc. (RNA)1 filingAvidity Biosciences, Inc. (RNAM)8 filingsUpdated Aug 31, 2026
Steven George Hughes is Chief Medical Officer of Atrium Therapeutics, Inc. (RNA). 9 SEC Form 4 filings on record going back to 2025, most recently on 22 April 2026. Most recent open-market trade: sold $209K of RNAM on 23 January 2026. Lifetime open-market sales: $4.27M.
Every recent SEC Form 4 transaction Steven George Hughes has reported, most recent first.
InsiderAlpha's records for Steven George Hughes go back to 2025: 9 primary Form 4 filings, an average of 4.5 per year. 5 recorded transactions carry a Rule 10b5-1 flag, meaning they were pre-scheduled under a written trading plan rather than discretionary.
Insiders who reported open-market trades in the last 12 months at the companies Steven George Hughes files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Steven George Hughes is a corporate insider, tracked as Chief Medical Officer of Atrium Therapeutics, Inc. (RNA). InsiderAlpha holds 9 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
The most recent primary Form 4 on record is dated 22 April 2026, one of 9 filings going back to 2025.
Recorded transactions: 0 open-market purchases and 12 open-market sales ($4.27M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
$RNAM Avidity Biosciences, Inc.2.9K shares @ $72.45$209K